Psychedelic Identity Shift: A Critical Approach to Set And Setting

The qualitative analysis draws on three primary data sources from a historic open-label pilot trial of psilocybin-assisted smoking cessation run at Johns Hopkins between 2008 and 2014: the study's Psilocybin-Facilitated Smoking Cessation Treatment Manual (a document of over 100 pages), 43 anonymised written ‘‘experience reports’’ provided by all 15 participants after dosing sessions, and published articles about the pilot study. The original pilot trial reported unusually high cessation rates (80% biologically verified abstinence at six months, 67% at 12 months, and 60% at long-term follow-up), and psilocybin was administered in two to three dosing sessions (first dose 20 mg/70 kg, subsequent doses 30 mg/70 kg). The first psilocybin session coincided with the participants' Target Quit Date (TQD). Data analysis was conducted from 2019–2020 by Devenot, Seale-Feldman, and Smith and combined approaches from narrative analysis in anthropology, close reading from literary studies, and elements of Interpretive Phenomenological Analysis. The study team triangulated the treatment manual, participant reports, and the published trial literature by Johnson, Garcia-Romeu, and Noorani to identify emergent themes related to self, identity, and smoking. Coding emphasised parallels between manualised therapeutic elements (for example, CBT-derived modules, mnemonic devices such as NURD and WEST-D, the NOGO program, guided imagery scripts, and personal quit mantras) and the imaginal or interpretive content of session narratives. The analysts explicitly avoided making causal claims about priming versus spontaneous phenomenology and treated the manual as a central contextual source to trace how therapeutic framing might map onto subjective reports.

Three interrelated patterns emerged from the triangulation of the manual and participant narratives: (1) rapid formation or consolidation of a ‘‘non-smoker’’ identity, (2) visible correspondences between manualised priming materials and imaginal content during sessions, and (3) a diversity of self-related experiences that extend beyond the conventional construct of ‘‘ego dissolution.’’ First, many participants described an abrupt and sometimes astonished shift to being a ‘‘non-smoker.’’ Across reports from first, second, and third dosing sessions, participants frequently characterised quitting as surprisingly simple, reporting an immediate loss or attenuation of craving and a new self-categorisation as a non-smoker. Illustrative examples include statements that cravings felt unreal or easily controlled and accounts of not missing cigarettes; several reports emphasised the adoption of a quit-related personal mantra (for example, ‘‘I'm so proud to have quit smoking for life’’) as part of maintaining that identity. Second, the content of participants' visions and insights often mirrored specific elements of the treatment manual. The manual included CBT-derived mnemonic devices (NURD, WEST-D), the NOGO program (emphasising ‘‘never even a puff’’), guided imagery scripts with archetypal scenes (e.g. ‘‘Shadow Guided Imagery’’ that externalised nicotine addiction as a parasitic ‘‘shadow’’ or a balloon to be stepped out of), scented-oil prompts, and pre-session autosuggestion exercises. The authors document concrete overlaps: for instance, Participant 402 reported a visual motif of one cigarette replicating into many—an insight that closely parallels the manual's messaging that ‘‘one cigarette is never just one.’’ Several participants recounted imagery and metaphors (the shadow, the balloon, exorcism of addiction) that align with guided-imagery language in the manual. Third, while some participants reported experiences consistent with standard measures of mystical-type ego dissolution (nine participants described episodes approaching conventional ‘‘complete’’ self-loss), others described a richer diversity of identity-related phenomena. Narratives included feelings of multiplicity (becoming or accessing other selves or ages, meeting a ‘‘little girl’’ self, or embodying a ‘‘goddess’’), enhanced interconnection with humanity or nature, discoveries of repressed personalities, and the perception that ordinary personality configurations were intentional and modifiable. The authors note that many such experiences were not fully captured by the Mysticism Scale items used in the trial and that ego dissolution may be multidimensional rather than a single binary state. Importantly, the analysis also found instances where reported phenomenology did not appear to be reducible to priming—participants sometimes described novel insights or self-experiences that exceeded preparatory suggestions. Finally, the authors emphasise that, given the congruence between manual content and participant reports, set and setting as operationalised by the manual may have influenced both the content and the perceived meaning of psychedelic experiences; however, they refrain from asserting direct causation based on the available data.

Ahmad and colleagues interpret their findings as evidence that therapeutic frameworks embedded in treatment manuals can meaningfully shape the content and interpretive framework of psychedelic experiences, thereby contributing to rapid identity shifts that are posited as mechanisms of smoking-cessation efficacy. They argue that the combination of suggestion-enhancing pharmacology, proposed increases in neural and psychological plasticity during psychedelic states, a participant's motivation to change, and explicit CBT priming creates fertile conditions for rapid reconfiguration of self-concept—most centrally, adopting a non-smoker identity. The authors situate these observations within PRIME theory and the broader smoking-cessation literature, noting that identity change has been theorised and empirically associated with reduced relapse risk. They further contrast psychedelic-assisted identity shift with identity changes discussed in the deep-brain stimulation (DBS) neuroethics literature: whereas DBS-related changes are often framed as unwanted side-effects, participants in this psilocybin study reported increased authenticity and agency. This difference, they contend, signals the need for novel neuroethical work tailored to psychedelic interventions rather than simple extrapolation from DBS debates. Key limitations and uncertainties are acknowledged. The extracted text emphasises that causal inferences about priming cannot be established from these retrospective narratives and manual comparisons; the authors therefore call for empirical tests of how preparatory materials and consent language affect in-session phenomenology. Measurement limitations are also noted: standard measures used in psychedelic trials (for example, the Mysticism Scale and ‘‘Big Five’’ personality inventories) may not capture the full range of PIAAAS outcomes (personality, identity, agency, authenticity, autonomy, and self) that ethicists and clinicians care about. The paper recognises the historical abuses associated with attempts to alter identity and urges caution, noting that therapeutic techniques capable of reshaping motivation and selfhood carry potential for misuse if deployed without safeguards. For research and practice, the authors recommend several steps: development and use of validated instruments for tracking identity change (they mention measures such as the Positive Smoker Identity Questionnaire and the Self-Concept and Identity Measure), experimentally varying consent language and preparatory materials to test priming effects, and making treatment manuals publicly available so that contextual influences on reported subjective effects can be examined. Ethically, they call for ‘‘enhanced consent’’ processes that explicitly address the potential for personality and identity change and for interdisciplinary engagement (including consultation with psychedelic-using communities) to guide normative frameworks as psychedelic medicine scales.

The authors conclude that psychedelic-assisted identity shift is a plausible therapeutic mechanism in addiction treatment that has been underexamined. Given the documented correspondences between manualised therapeutic framing and patient narratives, they argue that psychedelic research should adopt a critical approach to set and setting that includes transparent reporting of treatment manuals and preparation procedures. To protect autonomy and maximise ethical deployment, the authors urge formalisation of measurement, enhanced consent processes, and empirical testing of how priming influences subjective experience and clinical outcomes, while warning against the historical dangers of technologies aimed at changing identity.